Guayana Goldstrike Inc

Jun 01, 2017 (TheNewswire.ca via COMTEX) — (via TheNewswire) June 1, 2017, GYA, / TheNewswire / Vancouver, British Columbia – Guyana Goldstrike Inc. (the “Company” or “Guyana Goldstrike”) (GYA) is pleased to provide a progress report on the Company’s achievements for its shareholders and potential new investors. Peter Berdusco, Guyana Goldstrike’s President and CEO, commented: “We are extremely proud of our accomplishments that have been achieved to date. We have successfully completed the acquisition of the Marudi Gold Project and

May 25, 2017 – Vancouver, British Columbia – Guyana Goldstrike Inc. (the “Company” or “Guyana Goldstrike”) (TSXV: GYA) is pleased to announce the launch of its corporate website. The Company, in connection with its recent acquisition of Romanex Guyana Exploration Ltd., rebranding and name change from “Swift Resources Inc.” to “Guyana Goldstrike Inc.” is pleased to announce the launch of its corporate website, at www.guyanagoldstrike.com. The new website features up-to-date information on the Company’s flagship property the Marudi Gold Project, as

MONTREAL, QC, Apr 29, 2014 (Marketwired via COMTEX) — Sunshine Biopharma, Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer today announced that it has entered into an Investment Agreement with Dutchess Opportunity Fund, II, LP (“Dutchess”). Dutchess has agreed to purchase up to $2.5 million of shares of Sunshine’s Common Stock over a three-year commitment period. Under the terms of the Investment Agreement Sunshine

Premier Biomedical (PublicWire.com Press Release) —Premier Biomedical, Inc. (OTCQB: BIEI) today announced that President and Chief Executive Officer, William A. Hartman, was recently interviewed for a second time in 16 months by CEO/CFO Magazine, an independent investment publication which conducts interviews with company CEOs. The latest William Hartman interview appears in the publication’s Biotechnology and Pharmaceuticals Report available by calling (570) 851-1745 or via CEO/CFO Magazine Online (http://www.ceocfointerviews.com). (The original interview was in the October, 2012 edition.) In the interview,